BTK (targeted protein degrader); Ikaros/Aiolos (IKZF1/IKZF3)
Assets acting on this target.
- Class
- Cereblon-recruiting BTK degrader with IMiD activity
Assets acting on this target.
1 of 1 assets (1 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| Zelebrudomide | Nurix Therapeutics, Inc. | BTK (targeted protein degrader); Ikaros/Aiolos (IKZF1/IKZF3) | Relapsed/Refractory B-Cell Malignancies | Ph 1 | Company-directed Phase 1 disclosed in NRIX 10-K (2026-01-28) | source ↗ |